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From drug misuse to useful drugs
Introduction
Psychotic disorders such as schizophrenia are het-
erogeneous and often debilitating conditions that 
contribute substantially to the global burden of 
disease.1 Patients with psychosis present with a 
range of psychopathology across positive, negative 
and cognitive symptom domains. The introduc-
tion of dopamine (primarily D2) receptor antago-
nists in the 1950s revolutionised the treatment of 
psychotic disorders and they remain the mainstay 
of our treatment arsenal for psychosis.2 However, 
a significant proportion of patients either do not 
respond to traditional antipsychotics or do not 
achieve a complete or adequate remission of 
symptoms.3 In addition, most current antipsy-
chotics only target the positive symptoms of psy-
chosis, with little effect on negative or cognitive 
symptoms.2 Dopamine-acting antipsychotics are 
also associated with a number of side effects,4 
some of which can be severe and which may con-
tribute to nonadherence. There is therefore a need 
for novel interventions, particularly those with a 
non-D2 antagonist mechanism of action, and 
which may thereby avoid some of the adverse 
effects of modulating the dopamine system 
directly. In line with this, over recent years there 
has been increasing interest in the development of 
treatments with alternate mechanisms of action.5
Accumulating evidence implicates the endo-
cannabinoid system in the pathophysiology of 
psychosis.6,7 A recent meta-analysis concluded 
that patients with psychosis have significantly 
higher levels of the endocannabinoid anandamide 
both in cerebrospinal fluid and in blood, and 
higher expression of the main central cannabinoid 
1 receptor (CB1) on peripheral immune cells.8 
This elevated endocannabinoid tone was observed 
at all stages of illness, from the prodrome to 
chronic psychosis.8 Alterations in CB1 receptor 
expression have also been observed in  postmortem 
tissue and in vivo in patients with psychosis.9–11  
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If the endocannabinoid system plays a role in psy-
chosis pathophysiology, it raises the interesting 
possibility that pharmacological compounds that 
modulate this system may have therapeutic value.
Cannabidiol (CBD), a phytocannabinoid constit-
uent of Cannabis sativa, has been heralded as 
one such potential treatment. While the main 
psychoactive ingredient in cannabis, delta-
9-tetrohydrocannabinol (THC), has anxiogenic, 
psychotomimetic and amnestic effects, CBD is 
non-intoxicating and has potential anxiolytic, 
antipsychotic and anticonvulsant properties, and 
no detrimental effects on memory.12 Epidemio-
logical findings support these opposing effect 
 profiles; extensive evidence implicates cannabis 
use as a risk factor for the development of 
 psychosis and poor outcomes in cannabis-using 
 patients.13,14–19 However, the adverse effects of 
cannabis use on the risk of onset and subsequent 
outcome in psychosis are particularly evident in 
those using high potency skunk-like cannabis (i.e. 
with high levels of THC and low levels of CBD) 
as opposed to those using hash-like cannabis (i.e. 
with lower THC and higher CBD).15,20–22 This 
pattern of findings is consistent with evidence 
that CBD not only has opposing effects to THC 
but may also block some of its adverse (and par-
ticularly psychotomimetic) effects.23,24
Importantly, CBD has a different mechanism of 
action to dopamine receptor antagonists and 
could therefore represent a completely novel class 
of antipsychotic treatment.25 This would be asso-
ciated with numerous benefits. First, by avoiding 
dopamine receptor antagonism, adverse effects 
such as extrapyramidal symptoms and increased 
prolactin may be avoided. Second, if CBD acts 
via different molecular pathways to current antip-
sychotics, it could be used not only as monother-
apy but potentially as an adjunctive treatment 
alongside existing antipsychotics, with potential 
complementary gains in efficacy. While CBD is 
currently being tested in relation to a number of 
psychiatric disorders and physical health condi-
tions,12 this review synthesises and summarises 
the current evidence regarding the therapeutic 
potential of CBD as a treatment for psychosis.
Evidence for antipsychotic potential of 
cannabidiol
The accumulating evidence regarding the antipsy-
chotic potential of CBD has emerged from a num-
ber of different sources. This includes preclinical 
work, experimental studies in healthy human vol-
unteers comparing the neurocognitive effects of 
THC and CBD as well as studies examining 
whether CBD can block or attenuate the sympto-
matic effects of THC.
Preclinical evidence
Indirect evidence for the antipsychotic and anxio-
lytic effects of CBD comes from preclinical stud-
ies, where specific features of psychotic disorders 
are modelled in animals and allow potential ther-
apeutic effects to be examined from molecular to 
behavioural levels.26
Hyperlocomotion. Hyperlocomotion is thought to 
be a model of positive psychotic symptoms and 
can be rescued using antipsychotics.26 CBD has 
been shown to reduce hyperlocomotion induced 
by amphetamine (dopamine agonist) and ket-
amine [N-methyl-d-aspartate (NMDA) receptor 
antagonist] while at the same time not inducing 
catalepsy,27 which suggests that it has antipsy-
chotic-like beneficial effects without the detri-
mental motor side effects, with a profile resembling 
that of the atypical antipsychotic clozapine.28
Pre-pulse inhibition deficits. Pre-pulse inhibition 
(PPI) deficits represent sensorimotor gating 
abnormalities, thought to be a stable trait (bio)
marker that is present across the psychosis 
 spectrum.29 Peripubertal CBD has been found to 
prevent the development of PPI deficits in the 
spontaneously hypertensive rat strain model,30 
which suggests that CBD may have long-lasting 
prophylactic effects, while it did not negatively 
impact PPI in control mice.
Social withdrawal and cognition. Methylazoxy-
methanol treatment induces numerous behavioural 
and cognitive deficits (social interaction and novel 
object recognition) as well as a range of pathophysi-
ological manifestations analogous to those in 
schizophrenia,31 including altered CB1 expression 
in prefrontal cortex. Peripubertal CBD reversed 
the methylazoxymethanol-induced alterations in 
CB1 expression and the schizophrenia-like pheno-
type, neither of which are rescued by haloperidol.32 
CBD has been found to reduce social withdrawal 
induced by THC but not polyinosinic-polycytidylic 
acid.33,34 CBD can also attenuate MK-801 (an 
NMDA receptor antagonist)-induced changes in 
social behaviours, cognition and expression of vari-
ous glial markers.35 These latter findings suggest 
potential neuroprotective and anti-inflammatory 
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properties of CBD,12 which is supported by inde-
pendent evidence that CBD can promote hippo-
campal neurogenesis and rescue memory 
function,36,37 consistent with human studies show-
ing that CBD attenuates THC-elicited cognitive 
impairment.23,38
Human experimental and neuroimaging studies
Complementary insight into the antipsychotic 
potential of CBD has come from neuroimaging 
studies, which provide a means to noninvasively 
examine the systems (i.e. neural substrates) on 
which CBD may act to produce its antipsychotic 
and anxiolytic effects in vivo.
THC and CBD have been shown to have opposite 
effects on regional brain activation across a variety 
of cognitive tasks in healthy individuals.24 
Interestingly, this has been found in brain regions 
where patients with psychosis show dysfunction 
and during tasks that are known to be impaired by 
cannabis use. Using a double-blind, placebo- 
controlled, repeated-measures design, 15 healthy 
volunteers were studied on three occasions with 
functional magnetic resonance imaging (fMRI) 
after receiving a single dose of CBD (600 mg), 
THC (10 mg) or placebo.24 In this series of experi-
ments, THC-induced psychotic symptoms were 
directly related to the attenuating effects of THC 
on striatal activation during verbal recall and sali-
ence processing,24,39 suggesting that the psychoto-
genic effects of THC may be mediated in part by 
effects on the striatum. In contrast, CBD aug-
mented activation in the same regions during the 
task and did not induce psychotic symptoms. 
When viewing fearful faces, THC augmented acti-
vation in the amygdala, which was associated with 
induction of anxiety symptoms and increased 
physiological anxiety (measured using skin con-
ductance response).24 Conversely, CBD attenu-
ated amygdala activation and this was significantly 
associated with the concurrant CBD-induced 
decrease in physiological anxiety (skin conduct-
ance response), suggesting that these effects may 
account for the anxiolytic properties of CBD. 
THC and CBD also had directly opposing effects 
on activation in the hippocampus during response 
inhibition,24 the superior temporal cortex when 
listening to speech,24 the occipital cortex during 
visual processing and on functional connectivity 
within regions processing attentional salience.24,40
Further evidence for the protective effects of 
CBD against the psychotomimetic, anxiogenic, 
and cognition-impairing effects of THC comes 
from experimental studies where the two cannab-
inoids have been co-administered. THC can be 
used as an experimental model of psychosis in 
humans because its acute administration in 
healthy individuals can induce transient psy-
chotic-like symptoms (including both positive 
and negative symptoms), as well as cognitive defi-
cits resembling those seen in schizophrenia.41–47 
In one study, six healthy volunteers received 
intravenous THC (1.25 mg) on two occasions, 
once preceded by intravenous placebo and once 
by CBD (2.5 mg) in a double-blind, within- 
subject design.24 At the group level, THC admini-
stration with placebo pretreatment was associated 
with transient psychotomimetic effects, which 
was not observed under the CBD pretreatment 
condition.24 A larger between-group study 
(n = 48) showed that relative to placebo, pretreat-
ment with 600 mg oral CBD reduced the para-
noia and impairments in episodic memory elicited 
by 1.5 mg intravenous THC.23
In summary, a growing body of literature suggests 
that CBD attenuates the propsychotic, anxiety 
and cognitive effects elicited by THC in healthy 
individuals at both the neurophysiological and 
behavioural (psychopathological) level. In addi-
tion, CBD has opposite effects to THC on 
regional brain activation and functional connec-
tivity across a range of cognitive tasks (including 
salience processing, learning and memory, 
response inhibition and fear processing) in 
regions known to be disrupted in patients with 
 psychosis.24,39,40 Together, this accumulating 
 evidence supports a potential therapeutic role for 
CBD in the treatment of psychosis and is 
 consistent with independent evidence that CBD 
has antipsychotic effects in patients with the 
 disorder (see below).
Cannabidiol in psychosis: current clinical 
evidence
Positive and negative psychotic symptoms
Initial studies. The 1990s saw the first studies 
investigating the effects of CBD in patients with 
psychosis. Results from a single (n = 1) case study 
of a 19-year-old female with acutely exacerbated 
schizophrenia reported that oral CBD, titrated up 
to 1500 mg/day over 4 weeks, was associated with 
a reduction in psychotic symptoms as measured 
with the Brief Psychiatric Rating Scale (BPRS).48 
A subsequent case series examined the effects of 
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oral CBD monotherapy (up to 1280 mg/day) for 
30 days in three patients with treatment-resistant 
schizophrenia.49 Here, one patient showed mild 
improvement in BPRS scores while two did not, 
but CBD was well tolerated: there were no side 
effects reported even up to the maximum dos-
age.49 CBD has now been investigated in a num-
ber of larger-scale studies including randomised 
controlled trials (Table 1). The current review 
was not intended to be a fully systematic review, 
but to our knowledge, the information regarding 
previous clinical trials of CBD in psychosis is a 
complete and accurate record of all relevant stud-
ies up to July 2019.
CBD as monotherapy. One of the first landmark 
studies in patients with schizophrenia compared 
up to 800 mg/day of oral CBD with up to 800 mg/
day of the antipsychotic amisulpride. In a ran-
domised, double-blind, parallel-arm trial, 39 
patients with an acute exacerbation of schizo-
phrenia symptoms were treated over 4 weeks.53 By 
day 28, there was a significant reduction in posi-
tive symptoms, as measured using the Positive 
and Negative Syndrome Scale (PANSS), in both 
the CBD group (change from baseline to day 28; 
M ± SD = –9.0 ± 6.1, p < 0.001) and the amisul-
pride group (–8.4 ± 7.5, p < 0.001), with no sig-
nificant difference in efficacy between the 
treatments.53 This pattern of findings emerged 
also for negative, total and general symptoms, 
with significant reductions by day 28 in both 
treatment arms (all change-from-baseline com-
parisons p < 0.001), and no significant between-
treatment differences. These findings were the 
first robust indication that CBD may have anti-
psychotic efficacy, given the suggestion of nonin-
feriority to the D2/D3 antagonist amisulpride. 
However, the most striking findings came from 
the evaluation of side effects. Extrapyramidal 
symptoms, weight gain and increased prolactin 
are common side effects of antipsychotics4; amis-
ulpride significantly increased each of these 
parameters from baseline to day 28 (all p < 0.05).53 
However, no significant change was found in any 
of these side effects in the CBD group, and the 
between-treatment difference was significant (all 
p < 0.01), with CBD demonstrating a markedly 
superior side-effect profile.53 The finding of 
greater tolerability, against a backdrop of similar 
efficacy, is particularly promising because compli-
ance and adherence to current antipsychotic 
treatments are hindered by their often severe side-
effect profiles.4 Nonadherence, in turn, is associ-
ated with poorer prognosis (such as a more severe 
relapsing-remitting course) and worse functional 
outcomes.58 A novel antipsychotic without such 
side-effects could therefore lead to improved 
adherence and better outcomes. Finally, with a 
view to understanding the mechanisms by which 
CBD may have its antipsychotic effects, serum 
anandamide concentrations were measured 
before and after treatment in both groups.53 As 
predicted by the authors, anandamide levels were 
significantly higher in the CBD-treated group 
relative to the amisulpride group, but perhaps 
more interesting was the finding of a significant 
association between the increase in anandamide 
and reduction in psychotic symptoms in the CBD 
group (p = 0.0012).53 These findings support the 
idea that the antipsychotic effects of CBD may be 
related to its inhibition of anandamide degrada-
tion.53 This concurs with previous work showing 
that anandamide levels are increased in psychotic 
disorders (as reviewed by Minichino and col-
leagues)8 with higher levels associated with less 
severe symptomatology.59–62
CBD as adjunctive treatment. More recently, in a 
6-week multicentre, randomised, double-blind, 
parallel-group trial, CBD (1000 mg/day; n = 43) 
was compared with placebo (n = 45) as an add-on 
treatment to existing antipsychotic regimens in 
patients with schizophrenia.55 There was a signifi-
cant reduction in PANSS positive symptoms from 
baseline to 6-week study endpoint in the CBD 
compared with the placebo group (PANSS treat-
ment difference = −1.4, 95% CI = −2.5 to −0.2; 
p = 0.019). CBD-treated patients were also more 
likely to have been rated as improved (Clinical 
Global Impression Scale; CGI-I treatment differ-
ence = −0.5, 95% CI = −0.8 to −0.1; p = 0.018) 
and as not severely unwell (–0.3, 95% CI = −0.5 to 
0.0; p = 0.044) by the treating clinician.55 Although 
the magnitude of these effects appears modest, it 
is common for treatments to fail in add-on trial 
designs because the tested treatment needs to 
show an effect over and above that of the existing 
treatment (here, antipsychotics, which have rela-
tively large effect sizes).4,63,64 The fact that CBD 
produced such an additional effect over that of 
concomitant antipsychotic treatment is therefore 
promising. There were also numerical (but non-
significant) increases in the level of general func-
tioning [Global Assessment of Functioning (GAF) 
scale treatment difference = 3.0, 95% CI = −0.4 to 
6.4; p = 0.08] and cognitive performance in the 
CBD treatment arm compared with the placebo 
arm, but no significant differences emerged in a 
number of other outcomes, including on negative, 
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Table 1. Overview of studies investigating cannabidiol in patients with psychosis.
Study Design CBD regimen Outcome 
assessment
Results
Zuardi48 One patient with schizophrenia; 
open label case-report
Up to 1500 mg/
day for 4 weeks
BPRS Significant reduction in positive 
symptoms
Zuardi49 3 treatment-resistant patients 
with schizophrenia; open-label 
monotherapy case series
Up to 1280 mg/
day for 4 weeks
BPRS Mild improvement in one patient, no 
response in two patients
Zuardi50 Six patients with Parkinson’s 
disease with psychotic 
symptoms; open-label pilot 
study
Up to 600 mg/
day for 4 weeks
BPRS, 
Parkinson 
Psychosis 
Questionnaire
Significant reduction in psychotic 
symptoms
Zuardi51 Two patients with bipolar I 
disorder experiencing a manic 
episode with psychotic features; 
rater-blinded case series
Up to 1200 mg/
day for 24 days
Young Mania 
Rating Scale, 
BPRS
No symptomatic improvement after 
CBD monotherapy either alone 
(n = 1) or in addition to improvements 
following CBD plus olanzapine (n = 1)
Hallak52 28 patients with schizophrenia; 
baseline performance compared 
with that after placebo (n = 10), 
300 mg CBD (n = 9) or 600 mg 
CBD (n = 9) administration 
1 month later
Single dose of 
300 or 600 mg
Stroop Colour 
Word Test
Stroop test performance significantly 
improved in placebo and 300 mg CBD 
group; numerical (nonsignificant) 
improvement in 600 mg CBD group
Leweke53 39 patients with schizophrenia; 
randomised, double-blind, 
monotherapy trial of CBD (n = 19) 
compared with the antipsychotic 
amisulpride (n = 20)
Up to 800 mg/
day for 4 weeks
BPRS, PANSS Significant reduction in positive, 
negative, total and general symptoms 
in both groups. Significantly fewer 
side-effects in CBD group
Leweke54 29 patients with schizophrenia; 
randomised, double-blind, 
placebo-controlled crossover 
study
600 mg/day for 
2 weeks
PANSS Numerical but nonsignificant 
improvement in psychotic symptoms 
associated with CBD treatment
McGuire55 88 patients with schizophrenia; 
randomised, double-blind trial 
of add-on CBD (n = 43) versus 
placebo (n = 45)
1000 mg/day 
for 6 weeks
PANSS, CGI, 
GAF, Cognition
Significant reduction in positive 
symptoms and CBD-treated patients 
more likely rated as improved/not as 
severely unwell by treating clinicians 
(CGI)
Boggs56 36 patients with schizophrenia; 
randomised, double-blind trial 
of add-on CBD (n = 18) versus 
placebo (n = 18)
600 mg/day for 
6 weeks
PANSS, 
MATRICS
No effects of CBD on cognition or 
positive, negative or total symptoms
Bhattacharyya57 33 patients at CHR for 
psychosis; randomised, double-
blind design; 16 CHR subjects 
assigned to CBD and 17 to 
placebo; 19 controls
Single dose of 
600 mg
fMRI (brain 
activation 
during verbal 
learning task)
CBD normalised brain function in 
CHR individuals in regions where 
CHR individuals showed abnormal 
activation under placebo
BPRS, Brief Psychiatric Rating Scale; CBD, cannabidiol; CGI, Clinical Global Impression Scale; CHR, clinical high risk; fMRI, functional Magnetic 
Resonance Imaging; GAF, Global Assessment of Functioning Scale; MATRICS, MATRICS Consensus Cognitive Battery (MCCB); PANSS, Positive and 
Negative Syndrome Scale.
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total and general PANSS scores.55 The number of 
adverse events was similar between the CBD 
(30 adverse events in 15 patients) and the placebo 
(35 adverse events in 16 patients) treatment arms, 
with the most common side effects including 
 diarrhoea, nausea and headache. Most side effects 
were mild and did not require intervention.
Using similar methodology in a 6-week, ran-
domised, parallel-group trial, Boggs and col-
leagues compared 600 mg/day adjunctive CBD 
versus placebo in 36 stable, antipsychotic-treated 
patients with chronic schizophrenia.56 In this lat-
ter study, there were no effects of adjunctive CBD 
relative to placebo on positive, negative or total 
PANSS symptoms, nor were there any effects on 
cognitive performance (the primary outcome of 
the trial, measured using the MATRICS consen-
sus battery; MCCB). In fact, only the placebo 
group were found to have improved MCCB com-
posite scores over time, which the authors suggest 
may be due to regression to the mean or practice 
effects, with this pattern not seen in the CBD 
group, perhaps due to increased sedation or 
inhibited learning effects.56 Overall, CBD was 
well tolerated, with no worsening of psychosis, 
mood, suicidality or movement side effects.
The reasons for the contrasting results with the 
two larger clinical trials remain unclear and war-
rant consideration.53,55 One factor could be the 
lower CBD dose (600 mg/day) used by Boggs and 
colleagues,56 compared with the higher doses of 
800 and 1000 mg/day in the earlier trials.53,55 
While 600 mg (even as a single acute dose) has 
been shown to modulate brain function across a 
variety of tasks in healthy individuals, and can 
prevent the acute induction of psychotic symp-
toms following THC,24 it is possible that a higher 
therapeutic dose is needed in the context of 
patients with psychosis.56 This is consistent with 
the results from a further earlier study, which also 
used 600 mg/day in patients with schizophrenia, 
and which showed nonsignificant results for total 
PANSS symptom reduction,54 although there 
were also a number of design issues associated 
with this study. Research conducted outside of 
the psychosis literature suggests that specific 
effects of CBD follow an inverted-U dose-
response curve. This could have pragmatic impli-
cations for CBD as a novel pharmacotherapy 
because individual-patient dose titration would 
introduce practical challenges in the clinic. In two 
studies testing multiple doses of acute CBD 
against anxiety induced by public speaking, only 
the intermediate doses of CBD (300 mg) signifi-
cantly reduced anxiety while lower and higher 
doses did not.65,66 Animal models of anxiety con-
firm this dose-response effect, with anxiolytic 
effects observed at lower doses which disappear at 
higher doses.12,67 However, the dose-response 
range is thought to be narrower for the anxiolytic 
compared with the antipsychotic effects of 
CBD,67,68 at least in preclinical studies.28 Higher 
doses are also likely required for antipsychotic 
versus anxiolytic effects (for review see Crippa and 
colleagues).12 Future research is required to 
determine the precise dose-response ranges for 
specific therapeutic (i.e. antipsychotic and anxio-
lytic) effects for specific psychotic disorders and 
other clinical popluations.12
Other possible factors that may explain lack of 
beneficial effect of CBD treatment in the study by 
Boggs and colleagues may relate to illness stage 
and symptom severity of the respective samples.56 
The participants in the negative Boggs and 
 colleagues study were older (mean age = 47) and 
had chronic schizophrenia with stable symptoms, 
whereas those in the study of Leweke and col-
leagues were younger (mean age = 30) and were 
included only if they specifically had an acute exac-
erbation of psychotic symptoms.53 This is reflected 
in the higher mean baseline symptom scores in the 
Leweke study (PANSS total = 93; positive = 24) 
compared with the Boggs and  colleagues study 
(total = 80; positive = 20).53,56 However, the nega-
tive findings are harder to reconcile with the posi-
tive findings of McGuire and colleagues,55 where 
the levels of symptoms were comparable (PANSS 
total = 80; positive = 18) and the mean age was 
41 years. The Boggs and colleagues and McGuire 
and colleagues studies also took a similar method-
ological approach (add-on design),55,56 although 
the McGuire study had much higher statistical 
power (n = 88 versus n = 36). Together, these find-
ings may suggest that younger patients in an earlier 
stage of illness may benefit more from CBD treat-
ment, potentially because intervening early arrests 
pathophysiological processes before more severe or 
enduring neural changes (that may be less amena-
ble to later intervention) take place.5 A further 
potential difference between the studies relates to 
the existing antipsychotic treatment regimens 
within the add-on design. While McGuire and col-
leagues provide specific data on the exact antipsy-
chotic medications used by their sample, only 
summary classification data are provided by Boggs 
and colleagues.55,56 Nevertheless, in comparison, 
over 90% of the antipsychotics used in both the 
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CBD and placebo groups from the McGuire study 
were second-generation, and only ~8% were first-
generation. However, in the Boggs study, 55% of 
the CBD group and 72% of the placebo group 
were taking second-generation antipsychotics, 
while 50% of the CBD group and 28% of the pla-
cebo group were taking first-generation. Current 
evidence suggests there are small but significant 
differences in efficacy between different individual 
antipsychotics within both first and second-gener-
ation classifications.4 It is therefore possible that 
the different baseline mix of concurrent antipsy-
chotics could be a contributing factor to the dis-
parity in results.
Potential effects of CBD on cognition
The psychopathology associated with psychotic 
disorders is often thought of in terms of positive 
and negative symptoms. However, cognitive dys-
function is a prominent feature that is strongly 
associated with loss of social/occupational func-
tion and disability.69,70 Cognitive symptoms are 
also refractory to any type of current treatment.2 
A number of initial studies have examined 
whether CBD may improve aspects of cognition 
in patients with psychosis.
As outlined above, the clinical trial by Boggs and 
colleagues observed no significant effects of CBD 
on cognition, which was the study’s primary out-
come.56 The largest clinical trial of CBD in 
patients with psychosis also assessed cognition, 
using the Brief Assessment of Cognition in 
Schizophrenia (BACS).55 While there were no 
statistically significant effects of CBD on cogni-
tion overall, there were numerical increases in 
BACS composite score, motor speed perfor-
mance and executive functioning in the CBD 
relative to the placebo group.55 Studies of CBD 
administration in healthy people also show that 
CBD can attenuate the acute amnestic effects of 
THC administration,23 while it does not appear 
to affect learning and memory in the absence of 
existing impairments.71
A separate study examined the acute effects of a 
single dose of CBD on cognitive function in 28 
patients with schizophrenia.52 Performance on 
the Stroop Colour Word Test, which indexes 
selective attention, was compared at baseline (no 
drug) to one of three parallel-arm conditions 
1 month later: placebo (n = 10), 300 mg CBD 
(n = 9) and 600 mg CBD (n = 9). While perfor-
mance improved (numerically) in all three arms 
from baseline to the second session, indicating a 
learning effect, only those receiving placebo and 
the lower CBD dose (300 mg) showed a statisti-
cally significant improvement.52 The authors sug-
gest that sedative effects of CBD may underlie the 
lack of improvement (related to learning/practice 
effects) in the higher-dose CBD group. Overall, 
whether CBD has beneficial effects on cognition 
in patients with psychosis is currently unclear and 
remains an important avenue for future research.
Early intervention: prior to psychosis onset
CBD has also been indicated for use prior to the 
onset of psychosis in patients at clinical high risk for 
the disorder. These individuals present with clini-
cally significant attenuated psychotic symptoms 
and have 20–30% risk of developing psychosis 
within 2 years.72 Accumulating evidence suggests 
that the pathophysiological processes driving psy-
chosis evolve over the course of the disorder, with 
the clinical high-risk state offering a unique oppor-
tunity for preventative inter vention.5 However, 
recent meta-analyses have concluded that existing 
treatments are not effective for preventing transi-
tion to psychosis nor for reducing symptoms,73,74 
representing a significant unmet clinical need. 
Furthermore, because many of these individuals 
will not transition to psychosis, pharmacotherapies 
also need to be safe and well tolerated.
Using a randomised, double-blind, placebo- 
controlled, parallel-arm design, 33 antipsychotic-
naive individuals at clinical high risk for psychosis 
and 19 healthy controls were studied using a verbal 
learning fMRI task.57 A total of 16 high-risk sub-
jects received a single oral dose of CBD (600 mg) 
and 17 received placebo. Control participants were 
not given any drug. The results showed that a sin-
gle dose of CBD normalised brain function in clin-
ical high-risk individuals in regions where high-risk 
individuals showed abnormal activation under pla-
cebo conditions. These specific regions, including 
the hippocampus, midbrain and striatum, are also 
strongly implicated in the pathophysiology of psy-
chosis onset.75,76 The normalisation of aberrant 
brain function in these regions by CBD could 
underlie the therapeutic effects observed in previ-
ous studies in patients with established psychosis 
and anxiety disorders.53,55,77
In terms of effects following continued treatment, 
results from the same study investigating the 
effect of 3-week treatment with CBD  (600 mg/day) 
on symptoms and functional brain activation are 
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awaited.78 In summary, initial evidence supports 
CBD as a potential novel treatment for people at 
clinical high risk for psychosis, and its benign 
side-effect profile as evident from other data (see 
below) makes it a particularly suitable candidate 
treatment for this patient group. Whether CBD 
can actually alter the course of the disorder and 
prevent the onset of psychosis will require larger-
scale clinical trials over longer durations. Such 
studies have recently been initiated and the results 
are anticipated to make a significant contribution 
to the evidence base.
Psychosis in nonschizophrenia spectrum 
disorders
Additional complementary evidence for the use of 
CBD in psychosis comes from a study of 
Parkinson’s disease psychosis. In a small, open-
label pilot study, six patients with Parkinson’s dis-
ease psychosis received oral CBD for 4 weeks, 
titrated from a mean dose of 150–400 mg/day in 
addition to their current treatment regimens.50 
CBD was associated with a significant decrease in 
psychotic symptoms and was well tolerated, with 
no side effects clinically observed. CBD also 
improved total scores on the Unified Parkinson’s 
Disease Rating Scale and did not worsen cogni-
tion or motor function. While caution is war-
ranted due to the small sample size and lack of 
placebo control, these results support the view 
that CBD is safe, well-tolerated and may have 
efficacy for the treatment of psychosis in non-
schizophrenia spectrum disorders. Phase II clini-
cal trials of CBD for Parkinson’s disease psychosis 
and behavioural symptoms (including psychotic 
symptoms) in Alzheimer’s disease are now being 
planned.
In addition to its antipsychotic properties, the 
wider pharmacological profile of CBD, which 
includes anxiolytic, sedative, anticonvulsant and 
thus potential mood-stabilising effects, raises the 
possibility of therapeutic potential for bipolar dis-
order (with or without psychosis) as well as uni-
polar mood disorders.12,79 Aside from anecdotal 
reports,79 CBD has so far been tested in two 
patients with bipolar I disorder experiencing a 
manic episode with psychotic features.51 Two 
female inpatients received placebo for 5 days, 
 followed by oral CBD titrated from 600 to 
1200 mg/day for 24 days. One patient received 
concomitant olanzapine between day 6 and 20, 
while the other patient did not. Symptoms were 
assessed using the BPRS and Young Mania 
Rating Scale. CBD provided no additional bene-
fit over that seen after combined CBD and olan-
zapine treatment in the first patient, and there 
was no benefit of CBD monotherapy in the sec-
ond patient.51 These negative findings concur 
with the lack of CBD effects seen in an animal 
(hyperlocomotion) model of mania.80 Nevertheless, 
whether CBD is effective for other specific symp-
toms in bipolar disorder (such as bipolar depres-
sion and anxiety) is currently unknown but clinical 
trials are now underway.12 While outside the remit 
of this review, it is also worth noting that CBD has 
purported antidepressant-like effects (albeit so far 
in preclinical studies), thought to be mediated by 
serotonin 5-HT1A receptors,81 which could sug-
gest therapeutic potential for mood disorders such 
as depression.12,28
Safety and side effects
While CBD has been found to be safe and well 
tolerated in the three (relatively short-term) clini-
cal trials in psychosis to date,53,55,56 the total vol-
ume of data is still small and thus insufficient 
adverse events may yet have accumulated. When 
measured in terms of ‘patient-years’ (i.e. the 
number of patients treated with a new drug mul-
tiplied by the duration of treatment), data from at 
least 1000 patient-years or more are recom-
mended for robust estimates of safety and tolera-
bility.82 This follows the notion that the greater 
the clinical use and experience of prescribing 
drugs in different clinical scenarios, the better 
(and more nuanced) our knowledge of its true 
risk-benefit profile. However, 1000 patient-years 
equates to, for example, 1000 patients taking 
CBD for 1 year or 500 patients for 2 years. The 
largest RCT of CBD in psychosis to date ran-
domised 43 patients to receive CBD for 6 weeks.55 
This highlights the significant gulf between the 
current state of knowledge and the benchmark for 
sufficient risk-benefit evidence. Larger ran-
domised controlled trials with longer durations of 
treatment are therefore needed.
Considering the wider literature (not restricted to 
studies in psychosis), doses of up to 1500 mg/day 
have been well tolerated in humans with few or 
no side effects, although such doses have mainly 
been administered to very few patients in case 
series reports.28,48,49 The first comprehensive 
review of CBD-related (in vivo and in vitro) side 
effects suggested that CBD is nontoxic in cell 
lines and has no adverse effects on physiological 
parameters such as heart rate, blood pressure and 
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body temperature, gastrointestinal transit, and 
psychomotor or psychological function.83 A sec-
ond review extended these findings and con-
firmed that overall, CBD has a favourable safety 
profile.84 However, CBD is not entirely side-effect 
free; in vitro work suggests that CBD may affect 
cell viability, fertilisation potential and drug 
transporter/P-glycoprotein function,83,84 and 
reports of (mostly mild) clinical adverse effects 
are starting to accumulate as the body of available 
literature becomes substantiated. The most com-
mon adverse effects in clinical studies include 
diarrhoea, tiredness or sedation, and changes in 
appetite and weight.83
Sedation. The idea that CBD may induce sedation 
is a recurring theme,52,56 and there are numerous 
purported links between the endocannabinoid sys-
tem and the sleep–wake cycle. One of the earliest 
studies showed that 600 mg of CBD induced seda-
tion in a small sample of healthy people.85 In peo-
ple with insomnia, a therapeutic effect suggestive 
of sedation (increased sleep time, less frequent 
awakenings) was noted after 160 mg/day CBD.86 
However, other studies have shown that CBD 
counteracts the sedative effects of THC,87 and a 
recent study investigating the effects of 300 mg 
CBD (versus placebo) on the sleep-wake cycle 
reported no effects on sedation, albeit this was in 
healthy individuals.88 A review concluded that this 
effect is dose-based, with lower doses having a 
stimulating effect on the sleep–wake cycle, but 
higher doses having a sedative effect.89 Given the 
aforementioned evidence that higher doses of 
CBD are likely needed to produce antipsychotic 
effects, particularly in patients with psychotic dis-
orders (e.g. 800 mg/day or more), sedative side 
effects may be particularly prevalent when used for 
this indication and warrant further investigation.
Gastrointestinal. Studies in epilepsy report diar-
rhoea in approximately 15–20% of CBD-treated 
individuals.90 In the largest study in patients with 
psychosis, 9% of those receiving CBD versus 4% 
receiving placebo reported this side effect.55 While 
the severity was often mild and resolved without 
treatment, the one withdrawal (out of n = 43) in the 
CBD group was due to nausea, diarrhoea, abdomi-
nal pain and vomiting.55 Despite the initial review 
by Bergamaschi and colleagues suggesting no 
effects on gastric motility,83 the emerging  pattern of 
findings is that diarrhoea is one of the most com-
mon side effects of CBD. This suggests that it does, 
in fact, increase gastrointestinal  transit in humans 
which could affect its ultimate acceptability.84
Hepatic drug metabolism. CBD is a potent inhibi-
tor of CYP3A4 and CYP2D6, which belong to 
the cytochrome P450 family of enzymes that 
together metabolise more than 60% of prescribed 
drugs, including many antidepressants, antipsy-
chotics and benzodiazepines.91–94 CBD could, 
therefore, have effects on the circulating concen-
trations of other medications.83 In the context of 
psychosis, where concomitant antipsychotic treat-
ment is likely, such effects could require careful 
monitoring and dose adjustment.
Liver enzymes. A meta-analysis of studies con-
ducted in epilepsy found that CBD was associ-
ated with significantly increased serum 
aminotransferases, with a risk ratio of 14.14 (95% 
CI = 4.48–44.60) in studies using 20 mg/kg 
CBD.91 While the potential for hepatic toxicity 
was identified in this meta-analysis, no events 
within the individual studies met criteria for last-
ing liver injury (i.e. based on bilirubin).91 Moni-
toring of hepatic function, particularly during the 
first 30 days of treatment, is therefore recom-
mended.91,95 Given the potentially serious nature 
and consequences of this potential side effect, 
future research should attempt to evaluate such 
effects (and in additional patient populations).
Unregulated over-the-counter CBD products. One 
consequence of the explosion of public interest in 
CBD is that a vast array of unregulated products, 
purporting to contain CBD, are now widely avail-
able from online and high-street stores.96 These 
products should explicitly not be used for medici-
nal purposes (for review see Freeman and col-
leagues)96 because they are unregulated, not 
pharmaceutical grade nor produced under good 
manufacturing practice conditions;96 their ingre-
dients and dose are uncontrolled, with existing 
evidence showing that dosage is highly variable 
and contrary to labelling97; and there is the poten-
tial for such products to be contaminated with 
high levels of other cannabinoids (such as 
THC),96–98 which could be detrimental to mental 
health and especially harmful to those with psy-
chotic disorders. At best, such products represent 
an expensive placebo due to the typically low 
doses of CBD per administration (e.g. 25 mg/dose 
compared with 600–1000 mg/day in clinical stud-
ies),48,55,96 but at worst, these products could be 
actively harmful due to the high risk of contami-
nation with other cannabinoids. This is particu-
larly the case for individuals with psychotic 
disorders, but also for children, young adults and 
adolescents, where cannabinoid exposure during 
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these critical periods of brain development and 
maturation could have particularly severe and 
enduring pervasive effects.99
In summary, CBD appears to show a favourable 
safety and tolerability profile but there remains 
a paucity of data, particularly in terms of chronic 
exposure in humans. Whether CBD has adverse 
effects on liver enzymes and hepatic metabo-
lism, and thus potential interactions with other 
drugs, remains an important avenue for future 
research. Going forward, future clinical trials 
should aim to collect explicit information 
regarding side effects. While these future stud-
ies may indeed show that CBD is associated 
with common gastrointestinal and possibly sed-
ative side effects, the risk–benefit ratio may still 
be favourable, especially when compared with 
the current status quo of treatments for psycho-
sis: antipsychotics.
Potential mechanisms underlying the 
antipsychotic effects of cannabidiol
The idea that CBD may have therapeutic poten-
tial emerged from observations that it has oppo-
site effects to THC at the pharmacological/
molecular, neural (systems) and behavioural 
level.24,28,42 The main molecular target for THC 
is the CB1 receptor, where it has partial agonist 
effects.25 The molecular mechanisms of CBD are 
less clear, but its demonstrable ability to attenu-
ate the effects of THC led to the notion that it 
may be an inverse agonist/antagonist at CB1 
receptors. Although, in contrast to THC, CBD 
has low affinity for CB1,25 it does appear to 
‘antagonise the agonists’ of this receptor even at 
relatively low concentrations,100 potentially via 
negative allosteric modulation.101
Another mechanism by which CBD may have 
antipsychotic effects is via upregulation of the 
endocannabinoid anandamide, likely by inhibiting 
its degrading enzyme, fatty acid amide hydro-
lase.53,102 This is consistent with the aforemen-
tioned findings of Leweke and colleageus,53 where 
CBD increased serum anandamide levels in 
patients with psychosis, with this increase 
 significantly associated with the concomitant 
reduction in psychotic symptoms. Additional 
pharmacological effects of CBD that have 
been described include activation of 5-HT1A 
receptors,103 transient receptor potential vanilloid 
type 1,102 GPR55 receptors and potentially vari-
ous other mechanisms.25,104,105,106
CB1 receptors are widely expressed in brain with 
the highest concentrations in mesocorticolimbic 
regions.107–110 Consistent with this distribution, 
based on human experimental studies involving 
cannabinoid administration, CB1 receptors 
appear to be involved in numerous cognitive pro-
cesses subserved by corticolimbic circuitry,44,111 
such as learning and memory,24,47 salience pro-
cessing,39,40 and response inhibition,24 which are 
also known to be impaired in patients with psy-
chosis.111 Abundant evidence from experimental 
studies of healthy volunteers shows that CBD 
modulates brain function (in the opposite direc-
tion to THC) during each of these cognitive pro-
cesses in their respective neural substrates.24,39,40,47 
This suggests that, at the brain systems level, the 
mechanism of the antipsychotic effects of CBD 
may be mediated through modulation of function 
of these neural substrates. Consistent with this, in 
patients at clinical high risk for psychosis, CBD 
was also found to normalise activation in key 
brain regions strongly implicated in psychosis 
onset and psychotic symptoms (such as the hip-
pocampus, midbrain and striatum).57,75,76
Conclusion
Initial clinical trials suggest that CBD is safe, 
well-tolerated and may have antipsychotic effects 
in patients with psychosis. There is some indica-
tion that CBD may be particularly effective in the 
early stages of the disorder, such as in patients at 
clinical high risk and those with first episode psy-
chosis. Neuroimaging research suggests that 
CBD may exert its therapeutic effects via modu-
lation of brain function in regions known to be 
altered in patients with psychosis across a variety 
of cognitive paradigms. Questions remain regard-
ing the full side-effect profile of CBD, with 
reports of increased liver enzymes and potential 
for hepatic toxicity, but the most commonly 
reported side effects (such as diarrhoea and seda-
tion) are likely to be both mild and benign. A 
more substantial body of evidence, including 
larger studies with longer-term CBD administra-
tion (e.g. up to 2 years), is required to accurately 
estimate the risk-benefit profile of CBD. Pending 
such evidence, if CBD treatment were ultimately 
associated mainly with common sedative and 
gastrointestinal side effects, these would likely 
still indicate a favourable tolerability profile com-
pared with the side-effect profiles of currently 
licensed antipsychotic treatments. Given that 
CBD has antipsychotic effects without directly 
acting on dopamine receptors, it could represent 
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a completely novel class of treatment for psycho-
sis. CBD may also have therapeutic value prior to 
the onset of frank psychosis in patients at clinical 
high risk for the disorder, and in patients with 
nonschizophrenia spectrum disorder psychosis, 
such as Parkinson’s disease. Unregulated over-
the-counter products containing CBD should 
explicitly not be used for medicinal purposes. In 
sum, CBD currently represents a promising 
potential novel treatment for patients with psy-
chosis. If the success observed in initial clinical 
studies are replicated in large-scale trials with 
chronic administration, CBD has the potential to 
become the first licensed nondopaminergic treat-
ment for psychosis.
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